CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 500 filers reported holding CRISPR THERAPEUTICS AG in Q2 2021. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $244,546 | -5.4% | 4,356 | -23.8% | 0.23% | -4.1% |
| Q1 2023 | $258,625 | +11.3% | 5,718 | 0.0% | 0.24% | +22.7% |
| Q4 2022 | $232,437 | -37.9% | 5,718 | 0.0% | 0.20% | -43.8% |
| Q3 2022 | $374,000 | +4.2% | 5,718 | 0.0% | 0.35% | +27.5% |
| Q1 2022 | $359,000 | -29.2% | 5,718 | -14.5% | 0.28% | -23.3% |
| Q4 2021 | $507,000 | -43.7% | 6,687 | -16.8% | 0.36% | -49.2% |
| Q3 2021 | $900,000 | -30.0% | 8,037 | +1.2% | 0.71% | -28.6% |
| Q2 2021 | $1,286,000 | +33.5% | 7,943 | +0.5% | 0.99% | +25.4% |
| Q1 2021 | $963,000 | -26.0% | 7,901 | -7.1% | 0.79% | +79.1% |
| Q4 2020 | $1,302,000 | +32.5% | 8,505 | -27.6% | 0.44% | +7.6% |
| Q3 2020 | $983,000 | +41.8% | 11,748 | +24.6% | 0.41% | +15.5% |
| Q2 2020 | $693,000 | – | 9,428 | – | 0.36% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |